Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pennsylvania
With
National Heart, Lung, and Blood Institute (NHLBI)
This is a prospective cohort study among adult patients requiring warfarin therapy. Patients presenting for anticoagulation will be identified at the start of therapy and followed throughout their course until they reach maintenance dose. We will then develop a dosing equation for warfarin using patient, environmental and genetic factors.
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All Caucasians and African Americans who are new to warfarin therapy
You may not be if
Under 21 years of age
Non caucasian
Non african american
Have an abnormal INR before warfarin or heparin therapy
Unable to provide consent
Clareo Health | Predictors of Anticoagulation Control on Warfarin Therapy
